Biodexa PharmaceuticalsBDRX
13F holders, Q4 2025 (December 31)8holders +4
3new positions
0sold out
$2.27avg. 13F price*
At the end of Q4 2025, 8 institutions reported holding Biodexa Pharmaceuticals PLC (BDRX) in their 13F filings, up 4 from Q3 2025. 3 opened new positions and 0 sold out. The largest holders were Sabby Management, LLC ($433K), Armistice Capital, LLC ($227K) and HRT Financial LP ($24K).
- Company
- Biodexa Pharmaceuticals PLC
- CUSIP
- 59564R880
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $684K |
| Exits | 0 | $0 |
All 13F filers, Q3 2025 → Q4 2025: 301,685 shares bought and 4,839 shares sold, net +296,846 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Sabby Management, LLC | 3.63% | New | 190,658 | $433K |
| Armistice Capital, LLC | 0.01% | New | 100,000 | $227K |
| HRT Financial LP | 0.00% | New | 10,583 | $24K |
| UBS Group AG | 0.00% | Reduce -69.7% | 2,100 | $5K |
| GAMMA Investing LLC | 0.00% | Add +31.4% | 1,777 | $4K |
| SBI Securities Co., Ltd. | 0.00% | Reduce -12.2% | 101 | $229 |
| Hilton Head Capital Partners, LLC | 0.00% | — | 30 | $68 |
| Rhumbline Advisers | 0.00% | Add +380.0% | 24 | $54 |
"% of holder's portfolio" is BDRX's weight in each manager's 13F, not the share of Biodexa Pharmaceuticals PLC the manager owns.